AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
ISOLATED LIMB PERFUSION IN PRIMARY AND RECURRENT MELANOMA - INDICATIONS AND RESULTS
Authors: LIENARD D EGGERMONT AM KROON BBR KOOPS HS LEJEUNE FJ
Citation: D. Lienard et al., ISOLATED LIMB PERFUSION IN PRIMARY AND RECURRENT MELANOMA - INDICATIONS AND RESULTS, Seminars in surgical oncology, 14(3), 1998, pp. 202-209
HYPERTHERMIC ISOLATED LIMB PERFUSION FOR THE TREATMENT OF SOFT-TISSUESARCOMAS
Authors: KOOPS HS EGGERMONT AMM LIENARD D KROON BBR HOEKSTRA HJ VANGEEL AN NIEWEG OE LEJEUNE FJ
Citation: Hs. Koops et al., HYPERTHERMIC ISOLATED LIMB PERFUSION FOR THE TREATMENT OF SOFT-TISSUESARCOMAS, Seminars in surgical oncology, 14(3), 1998, pp. 210-214
ACHIEVEMENTS AND PROSPECTS IN THE CLINICAL USE OF TNF
Authors: LEJEUNE FJ
Citation: Fj. Lejeune, ACHIEVEMENTS AND PROSPECTS IN THE CLINICAL USE OF TNF, European cytokine network, 9(3), 1998, pp. 500-500
EVIDENCE FOR THE INVOLVEMENT OF ENDOTHELIAL-CELL INTEGRIN ALPHA-V-BETA-3 IN THE DISRUPTION OF THE TUMOR VASCULATURE INDUCED BY TNF AND IFN-GAMMA
Authors: RUEGG C YILMAZ A BIELER G BAMAT J CHAUBERT P LEJEUNE FJ
Citation: C. Ruegg et al., EVIDENCE FOR THE INVOLVEMENT OF ENDOTHELIAL-CELL INTEGRIN ALPHA-V-BETA-3 IN THE DISRUPTION OF THE TUMOR VASCULATURE INDUCED BY TNF AND IFN-GAMMA, Nature medicine, 4(4), 1998, pp. 408-414
CLINICAL-APPLICATIONS OF TNF-ALPHA IN CANCER
Authors: LEJEUNE FJ RUEGG C LIENARD D
Citation: Fj. Lejeune et al., CLINICAL-APPLICATIONS OF TNF-ALPHA IN CANCER, Current opinion in immunology, 10(5), 1998, pp. 573-580
PROPHYLACTIC ISOLATED LIMB PERFUSION FOR LOCALIZED, HIGH-RISK LIMB MELANOMA - RESULTS OF A MULTICENTER RANDOMIZED PHASE-III TRIAL
Authors: KOOPS HS VAGLINI M SUCIU S KROON BBR THOMPSON JF GOHL J EGGERMONT AMM DIFILIPPO F KREMENTZ ET RUITER D LEJEUNE FJ
Citation: Hs. Koops et al., PROPHYLACTIC ISOLATED LIMB PERFUSION FOR LOCALIZED, HIGH-RISK LIMB MELANOMA - RESULTS OF A MULTICENTER RANDOMIZED PHASE-III TRIAL, Journal of clinical oncology, 16(9), 1998, pp. 2906-2912
HYPERTHERMIC ISOLATED LIMB PERFUSION WITH TUMOR-NECROSIS-FACTOR AND MELPHALAN AS TREATMENT OF LOCALLY ADVANCED OR RECURRENT SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
Authors: KOOPS HS EGGERMONT AMM LIENARD D KROON BBR HOEKSTRA HJ VANGEEL AN NIEWEG OE LEJEUNE FJ
Citation: Hs. Koops et al., HYPERTHERMIC ISOLATED LIMB PERFUSION WITH TUMOR-NECROSIS-FACTOR AND MELPHALAN AS TREATMENT OF LOCALLY ADVANCED OR RECURRENT SOFT-TISSUE SARCOMAS OF THE EXTREMITIES, Radiotherapy and oncology, 48(1), 1998, pp. 1-4
PULSE TREATMENT OF HUMAN VASCULAR ENDOTHELIAL-CELLS WITH HIGH-DOSES OF TUMOR-NECROSIS-FACTOR AND INTERFERON-GAMMA RESULTS IN SIMULTANEOUS SYNERGISTIC AND REVERSIBLE EFFECTS ON PROLIFERATION AND MORPHOLOGY
Authors: YILMAZ A BIELER G SPERTINI O LEJEUNE FJ RUEGG C
Citation: A. Yilmaz et al., PULSE TREATMENT OF HUMAN VASCULAR ENDOTHELIAL-CELLS WITH HIGH-DOSES OF TUMOR-NECROSIS-FACTOR AND INTERFERON-GAMMA RESULTS IN SIMULTANEOUS SYNERGISTIC AND REVERSIBLE EFFECTS ON PROLIFERATION AND MORPHOLOGY, International journal of cancer, 77(4), 1998, pp. 592-599
IN-MEMORIAM CARREL,STEFAN (1939-1996)
Authors: CEROTTINI JC LEJEUNE FJ
Citation: Jc. Cerottini et Fj. Lejeune, IN-MEMORIAM CARREL,STEFAN (1939-1996), Melanoma research, 7, 1997, pp. 5-5
CELL-DIFFERENTIATION AND CELL-CYCLE ALTERATIONS BY TYROSINE KINASE INHIBITORS IN HUMAN-MELANOMA CELLS
Authors: HARTMANN RR RIMOLDI D LEJEUNE FJ CARREL S
Citation: Rr. Hartmann et al., CELL-DIFFERENTIATION AND CELL-CYCLE ALTERATIONS BY TYROSINE KINASE INHIBITORS IN HUMAN-MELANOMA CELLS, Melanoma research, 7, 1997, pp. 27-33
LACK OF ANTITUMOR-ACTIVITY OF HUMAN RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA, ALONE OR IN COMBINATION WITH MELPHALAN IN A NUDE-MOUSE HUMAN-MELANOMA XENOGRAFT SYSTEM
Authors: FURRER M ALTERMATT HJ RIS HB ALTHAUS U RUEGG C LIENARD D LEJEUNE FJ
Citation: M. Furrer et al., LACK OF ANTITUMOR-ACTIVITY OF HUMAN RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA, ALONE OR IN COMBINATION WITH MELPHALAN IN A NUDE-MOUSE HUMAN-MELANOMA XENOGRAFT SYSTEM, Melanoma research, 7, 1997, pp. 43-49
PRINCIPLES AND GUIDELINES FOR SURGEONS - MANAGEMENT OF CUTANEOUS MALIGNANT-MELANOMA
Authors: KROON BBR NIEWEG OE HOEKSTRA HJ LEJEUNE FJ
Citation: Bbr. Kroon et al., PRINCIPLES AND GUIDELINES FOR SURGEONS - MANAGEMENT OF CUTANEOUS MALIGNANT-MELANOMA, European journal of surgical oncology, 23(6), 1997, pp. 550-558
ISOLATED LIMB PERFUSION WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA INCOMBINATION WITH INTERFERON-GAMMA AND MELPHALAN FOR NONRESECTABLE EXTREMITY SOFT-TISSUE SARCOMAS - A MULTICENTER TRIAL - REPLY
Authors: EGGERMONT AMM KOOPS HS LIENARD D KROON BBR VANGEEL AN HOEKSTRA HJ LEJEUNE FJ
Citation: Amm. Eggermont et al., ISOLATED LIMB PERFUSION WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA INCOMBINATION WITH INTERFERON-GAMMA AND MELPHALAN FOR NONRESECTABLE EXTREMITY SOFT-TISSUE SARCOMAS - A MULTICENTER TRIAL - REPLY, Journal of clinical oncology, 15(5), 1997, pp. 2174-2175
ISOLATION LIMB PERFUSION WITH TUMOR-NECROSIS-FACTOR-ALPHA AND CHEMOTHERAPY FOR ADVANCED EXTREMITY SOFT-TISSUE SARCOMAS
Authors: EGGERMONT AMM KOOPS HS KLAUSNER JM LIENARD D KROON BBR SCHLAG PM BENARI G LEJEUNE FJ
Citation: Amm. Eggermont et al., ISOLATION LIMB PERFUSION WITH TUMOR-NECROSIS-FACTOR-ALPHA AND CHEMOTHERAPY FOR ADVANCED EXTREMITY SOFT-TISSUE SARCOMAS, Seminars in oncology, 24(5), 1997, pp. 547-555
THE MANAGEMENT OF MALIGNANT-MELANOMA REVISITED
Authors: LEJEUNE FJ
Citation: Fj. Lejeune, THE MANAGEMENT OF MALIGNANT-MELANOMA REVISITED, Acta Chirurgica Belgica, 97(5), 1997, pp. 209-214
TNF-ALPHA - SHOCK-FREE CANCER REMISSION
Authors: LEJEUNE FJ LIENARD D
Citation: Fj. Lejeune et D. Lienard, TNF-ALPHA - SHOCK-FREE CANCER REMISSION, Nature biotechnology, 14(6), 1996, pp. 706
ISOLATED LIMB PERFUSION WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA INCOMBINATION WITH INTERFERON-GAMMA AND MELPHALAN FOR NONRESECTABLE EXTREMITY SOFT-TISSUE SARCOMAS - A MULTICENTER TRIAL
Authors: EGGERMONT AMM KOOPS HS LIENARD D KROON BBR VANGEEL AN HOEKSTRA HJ LEJEUNE FJ
Citation: Amm. Eggermont et al., ISOLATED LIMB PERFUSION WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA INCOMBINATION WITH INTERFERON-GAMMA AND MELPHALAN FOR NONRESECTABLE EXTREMITY SOFT-TISSUE SARCOMAS - A MULTICENTER TRIAL, Journal of clinical oncology, 14(10), 1996, pp. 2653-2665
INTRACELLULAR-LOCALIZATION AND INTERCELLULAR HETEROGENEITY OF THE HUMAN DNA-REPAIR PROTEIN O-6 METHYLGUANINE-DNA METHYLTRANSFERASE
Authors: BELANICH M RANDALL T PASTOR MA KIBITEL JT ALAS LG DOLAN ME SCHOLD SC GANDER M LEJEUNE FJ LI BFL WHITE AB WASSERMAN P CITRON ML YAROSH DB
Citation: M. Belanich et al., INTRACELLULAR-LOCALIZATION AND INTERCELLULAR HETEROGENEITY OF THE HUMAN DNA-REPAIR PROTEIN O-6 METHYLGUANINE-DNA METHYLTRANSFERASE, Cancer chemotherapy and pharmacology, 37(6), 1996, pp. 547-555
ISOLATED LIMB PERFUSION WITH TUMOR-NECROSIS-FACTOR AND MELPHALAN FOR LIMB SALVAGE IN 186 PATIENTS WITH LOCALLY ADVANCED SOFT-TISSUE EXTREMITY SARCOMAS - THE CUMULATIVE MULTICENTER EUROPEAN EXPERIENCE
Authors: EGGERMONT AMM KOOPS HS KLAUSNER JM KROON BBR SCHLAG PM LIENARD D VANGEEL AN HOEKSTRA HJ MELLER I NIEWEG OE KETTELHACK C BENARI G PECTOR JC LEJEUNE FJ
Citation: Amm. Eggermont et al., ISOLATED LIMB PERFUSION WITH TUMOR-NECROSIS-FACTOR AND MELPHALAN FOR LIMB SALVAGE IN 186 PATIENTS WITH LOCALLY ADVANCED SOFT-TISSUE EXTREMITY SARCOMAS - THE CUMULATIVE MULTICENTER EUROPEAN EXPERIENCE, Annals of surgery, 224(6), 1996, pp. 756-765
HIGH-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR (RTNF-ALPHA) ADMINISTEREDBY ISOLATION PERFUSION FOR ADVANCED TUMORS OF THE LIMBS - A MODEL FORBIOCHEMOTHERAPY OF CANCER
Authors: LEJEUNE FJ
Citation: Fj. Lejeune, HIGH-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR (RTNF-ALPHA) ADMINISTEREDBY ISOLATION PERFUSION FOR ADVANCED TUMORS OF THE LIMBS - A MODEL FORBIOCHEMOTHERAPY OF CANCER, European journal of cancer, 31A(6), 1995, pp. 1009-1016
THE EUROPEAN EXPERIENCE IN TNF-ALPHA ISOLATED LIMB PERFUSIONS FOR NONRESECTABLE EXTREMITY SOFT-TISSUE SARCOMAS - 85-PERCENT RESPONSE RATE, 87-PERCENT LIMB SALVAGE
Authors: EGGERMONT AMM KOOPS HS KROON BBR KLAUSNER JM SCHLAG PM LEJEUNE FJ
Citation: Amm. Eggermont et al., THE EUROPEAN EXPERIENCE IN TNF-ALPHA ISOLATED LIMB PERFUSIONS FOR NONRESECTABLE EXTREMITY SOFT-TISSUE SARCOMAS - 85-PERCENT RESPONSE RATE, 87-PERCENT LIMB SALVAGE, European journal of cancer, 31A, 1995, pp. 217-217
A RETROSPECTIVE COMPARATIVE-STUDY EVALUATING THE RESULTS OF MILD HYPERTHERMIC VERSUS CONTROLLED NORMOTHERMIC PERFUSION FOR RECURRENT MELANOMA OF THE EXTREMITIES
Authors: KLAASE JM KROON BBR EGGERMONT AMM VANGEEL AN KOOPS HS OLDHOFF J LIENARD D LEJEUNE FJ BERKEL R FRANKLIN HR HART AAM
Citation: Jm. Klaase et al., A RETROSPECTIVE COMPARATIVE-STUDY EVALUATING THE RESULTS OF MILD HYPERTHERMIC VERSUS CONTROLLED NORMOTHERMIC PERFUSION FOR RECURRENT MELANOMA OF THE EXTREMITIES, European journal of cancer, 31A(1), 1995, pp. 58-63
VWF RELEASE AND PLATELET-AGGREGATION IN HUMAN-MELANOMA AFTER PERFUSION WITH TNF-ALPHA
Authors: RENARD N NOOIJEN BTGA SCHALKWIJK L DEWAAL RMW EGGERMONT AMM LIENARD D KROON BBR LEJEUNE FJ RUITER DJ
Citation: N. Renard et al., VWF RELEASE AND PLATELET-AGGREGATION IN HUMAN-MELANOMA AFTER PERFUSION WITH TNF-ALPHA, Journal of pathology, 176(3), 1995, pp. 279-287
RAPID INCREASE IN PLASMA TENASCIN-C CONCENTRATION AFTER ISOLATED LIMBPERFUSION WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR (TNF), INTERFERON-GAMMA (IFN-GAMMA) AND MELPHALAN FOR REGIONALLY ADVANCED TUMORS
Authors: SCHENK S LIENARD D GERAIN J BAUMGARTNER M LEJEUNE FJ CHIQUETEHRISMANN R RUEGG C
Citation: S. Schenk et al., RAPID INCREASE IN PLASMA TENASCIN-C CONCENTRATION AFTER ISOLATED LIMBPERFUSION WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR (TNF), INTERFERON-GAMMA (IFN-GAMMA) AND MELPHALAN FOR REGIONALLY ADVANCED TUMORS, International journal of cancer, 63(5), 1995, pp. 665-672
ISOLATED PERFUSION OF THE LIMB WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA), INTERFERON-GAMMA (IFN-GAMMA) AND MELPHALAN FOR MELANOMA STAGE-III - RESULTS OF A MULTICENTER PILOT-STUDY
Authors: LIENARD D EGGERMONT AMM KOOPS HS KROON BBR ROSENKAIMER F AUTIER P LEJEUNE FJ
Citation: D. Lienard et al., ISOLATED PERFUSION OF THE LIMB WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA), INTERFERON-GAMMA (IFN-GAMMA) AND MELPHALAN FOR MELANOMA STAGE-III - RESULTS OF A MULTICENTER PILOT-STUDY, Melanoma research, 4, 1994, pp. 21-26
Risultati: 1-25 | 26-28